A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-1826|DRUG: SHR-4642|DRUG: SHR-9839|DRUG: SHR-8068|DRUG: Bevacizumab Injection|DRUG: Fluorouracil Injection|DRUG: Calcium Folinate Injection|DRUG: Adebrelimab Injection
RP2D (Phase 1), Screening up to study completion, an average of 1 year.|AE (Phase 1), Screening up to study completion, an average of 1 year.|Objective response rate (ORR) (Phase 2), Screening up to study completion, an average of 1 year.
Objective response rate (ORR) (Phase 1), Screening up to study completion, an average of 1 year.|Disease control rate (DCR) (Phase 1), Screening up to study completion, an average of 1 year.|Duration of response (DoR) (Phase 1), Screening up to study completion, an average of 1 year.|Progression-free survival (PFS) (Phase 1), Screening up to study completion, an average of 1 year.|Overall survival (OS) (Phase 1), Screening up to study completion, an average of 1 year.|Drug Resistant Antibody (ADA) (Phase 1), Screening up to study completion, an average of 1 year.|Blood concentration of SHR-1826 (Phase 1), Screening up to study completion, an average of 1 year.|Blood concentration of free toxin SHR169265 (Phase 1), Screening up to study completion, an average of 1 year.|Disease control rate (DCR) (Phase 2), Screening up to study completion, an average of 1 year.|Duration of response (DoR) (Phase 2), Screening up to study completion, an average of 1 year.|Progression-free survival (PFS) (Phase 2), Screening up to study completion, an average of 1 year.|Overall survival (OS) (Phase 2), Screening up to study completion, an average of 1 year.|AE (Phase 2), Screening up to study completion, an average of 1 year.
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.